Clinical Trial: Quetiapine Augmentation in Severe Obsessive Compulsive Disorder
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Quetiapine Augmentation in Severe Obsessive Compulsive Disorder (OCD) - Pilot Study
Brief Summary: The purpose of the study is to evaluate the efficacy of quetiapine or placebo added to baseline treatment of SSRI/clomipramine for the treatment of OCD in adult subjects.
Detailed Summary:
Sponsor: AstraZeneca
Current Primary Outcome: Absolute change of OCD symptoms from baseline to endpoint on the total Y-BOCS score.
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Change of comorbid psychiatric symptoms and measures of quality of life from baseline to endpoint documented by different scales.
- Evaluation of the safety and tolerability profile of quetiapine compared to placebo added to a baseline medication of SSRI/clomipramine.
Original Secondary Outcome: Same as current
Information By: AstraZeneca
Dates:
Date Received: November 15, 2005
Date Started: April 2002
Date Completion:
Last Updated: December 14, 2007
Last Verified: December 2007
